Angus Liu is a Deputy Editor at Fierce Pharma and Fierce Biotech. He focuses on the intersection of medicine and healthcare, particularly in pharmaceuticals, healthcare technology, and corporate finance, with a keen interest in topics such as pharmaceutical manufacturing, oncology, and digital health. Angus has been featured in Biotech, Fierce Pharma, and NewsBreak.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking licensing deals in China, experts say. For the first time, a federal jury has found a drugmaker liable in a pay-for-delay case. And more.
By: Angus Liu
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off.
By: Angus Liu
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block those deals have gotten louder.
By: Angus Liu
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s first-line non-small cell lung cancer data for its Summit Therapeutics
By: Angus Liu
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later.
By: Angus Liu
Nine years after wowing the audience at the American Society of Clinical Oncol
By: Angus Liu
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.
By: Angus Liu
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-
By: Angus Liu
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard
By: Angus Liu
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry.
